Ani Pharmaceuticals (ANIP) Income towards Parent Company (2011 - 2026)

Ani Pharmaceuticals has disclosed Income towards Parent Company across 16 years of filings, most recently posting $29.5 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at $29.5 million, up 88.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $92.1 million (up 537.89% YoY), and the FY2025 annual result was $78.3 million, up 522.94% from the prior year.
• Income towards Parent Company came in at $29.5 million for Q1 2026 at Ani Pharmaceuticals, up from $27.5 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $29.5 million in Q1 2026 to a low of -$24.2 million in Q3 2024.
• The 5-year median for Income towards Parent Company is $1.4 million (2023), against an average of $3.5 million.
• Across the five-year window, Income towards Parent Company slumped 23506.98% in 2022 and soared 1165.25% in 2024, its largest moves.
• Ani Pharmaceuticals' Income towards Parent Company stood at -$4.2 million in 2022, then surged by 127.2% to $1.2 million in 2023, then sank by 990.12% to -$10.3 million in 2024, then surged by 367.62% to $27.5 million in 2025, then grew by 7.28% to $29.5 million in 2026.
• The last three Income towards Parent Company figures came in at $29.5 million (Q1 2026), $27.5 million (Q4 2025), and $26.6 million (Q3 2025), per Business Quant data.